<

PARMANTIER & CIE. GMBH EQS-News: PARMANTIER & CIE. is starting coverage of CLINUVEL Pharmaceuticals Ltd.

Transparency directive : regulatory news

09/09/2024 15:10

Issuer: Parmantier & Cie. GmbH / Key word(s): Miscellaneous
PARMANTIER & CIE. is starting coverage of CLINUVEL Pharmaceuticals Ltd.

09.09.2024 / 15:10 CET/CEST
The issuer is solely responsible for the content of this announcement.


Frankfurt am Main, September 09, 2024 - PARMANTIER & CIE. has initiated coverage of CLINUVEL Pharmaceuticals Ltd., Melbourne. CLINUVEL Pharmaceuticals Ltd. is a biopharmaceutical company founded in 1987 and headquartered in Melbourne, Australia. The company is a leader in the development and commercialization of melanocortin-based therapies for the treatment of skin pigmentation disorders and the prevention of skin cancer. CLINUVEL is particularly well known for its flagship product SCENESSE®, an implanted drug for the treatment of the rare disease erythropoietic protoporphyria (EPP). In addition to the pharmaceutical division, CLINUVEL has also developed the nutraceuticals division to offer nutritional supplements to improve skin health.

CLINUVEL is positioned in two core sectors: pharmaceuticals and photocosmetics.

You can find our complete research report on CLINUVEL Pharmaceuticals Ltd. here:

Bloomberg/parmantiercie; Shortcode: {DS FMG <GO>}

https://www.parmantiercie.com/

Analyst Coverage - CLINUVEL

 

About PARMANTIER & CIE. Ltd:

PARMANTIER & CIE. specializes in advising and arranging corporate financing, be it equity, debt or hybrid forms of financing, pursuing the business approach of a traditional merchant bank. PARMANTIER & CIE. also invests in listed and unlisted companies. The company's guiding principles are the traditional values of an honorable businessman and the development of innovative financing solutions for a changing world. The company takes risks itself and always invests its own capital. The company is characterized by a forward-looking mindset as well as the design of tailor-made, modern corporate financing for listed and unlisted companies.

 

Contact

Melba Victoria Grün

gruen@parmantiercie.com



Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Parmantier & Cie. GmbH
Neue Mainzer Str. 66-68
60311 Frankfurt
Germany
Internet: https://www.parmantiercie.com
EQS News ID: 1984455

 
End of News EQS News Service

fncls.ssp?fn=show_t_gif&application_id=1984455&application_name=news&site_id=symex~~~af100301-a623-4c64-8f3d-90fc88eca9e6

source : webdisclosure.com

PARMANTIER & CIE. GMBH's latest news


18/11/2024 15:00
02/10/2024 11:27
09/09/2024 15:10
28/08/2024 09:00
04/06/2024 12:20


Other stories

21/12/2024 08:21
20/12/2024 19:34
21/12/2024 11:18
21/12/2024 10:26
21/12/2024 02:37
21/12/2024 02:53
21/12/2024 12:22
21/12/2024 10:53
21/12/2024 10:24
21/12/2024 02:43
20/12/2024 17:47
21/12/2024 12:35
20/12/2024 18:14
21/12/2024 11:39
21/12/2024 09:14
21/12/2024 06:05
21/12/2024 03:03
20/12/2024 19:39
20/12/2024 13:30
20/12/2024 14:03
21/12/2024 12:31
21/12/2024 09:57
21/12/2024 08:30
21/12/2024 06:18
20/12/2024 19:59
20/12/2024 16:50
21/12/2024 10:50
21/12/2024 12:24
21/12/2024 09:37
20/12/2024 15:22
21/12/2024 10:18
19/12/2024 16:12
20/12/2024 18:55
20/12/2024 11:49
20/12/2024 14:19
21/12/2024 11:00
20/12/2024 21:45
20/12/2024 13:26